Sign In
to Vote &
Create Storyboards.
 
Novartis has announced new data indicating that continued treatment with Gilenya® (fingolimod) led to a reduction in brain volume loss in people with relapsing remitting multiple sclerosis (RRMS), and was associated with a higher proportion of people remaining free of disability progression compared to placebo.1 These data were presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard